logo
  

PTC Receives Positive CHMP Opinion For Upstaza For Treatment Of AADC Deficiency

PTC Therapeutics Inc. (PTCT) said that Upstaza received a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the European Medicines Agency or EMA.

Once ratified by the European Commission, Upstaza will be the first approved disease-modifying treatment for aromatic L-amino acid decarboxylase (AADC) deficiency for patients 18 months and older and the first marketed gene therapy directly infused into the brain, the company said in a statement.

PTC expects the European Commission to ratify the marketing authorization for Upstaza under exceptional circumstances in about two months. The decision will be applicable to all 27 European Union member states, as well as Iceland, Norway and Liechtenstein.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Deutsche Post DHL Group were gaining around 6 percent in the morning trading in Germany after the package delivery and logistic major reported Friday higher profit and revenues in its second quarter with strong demand. Going ahead, the company confirmed its 2022 EBIT guidance of 8.0 billion euros, plus or minus 5 percent, even in consideration of a possible global economic downturn. Chinese e-commerce giant Alibaba Group Holdings Ltd. (BABA) reported Thursday net income for the first quarter halved from last year, hurt by a 1 decline in revenues and a decrease in the market prices of its equity investments in publicly-traded companies. Shares of Deutsche Lufthansa AG were gaining around 6 percent in the morning trading after the German flag carrier reported Thursday a profit in its second quarter, compared to last year's loss, benefited by surge in demand. The company also specified its outlook for the year, and now expects adjusted EBIT to be above 500 million euros for the full year of 2022, in line with current market.
Follow RTT